Developing new treatments for childhood solid tumors
PROTECT - Develop therapeutics to target oncogenic drivers of solid tumours in children
This study is working on new ways to treat tough childhood cancers by targeting specific proteins that help the tumors grow, using advanced techniques to find and stop these proteins, all with the goal of helping kids get better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | The Institute of Cancer Research: Royal Cancer Hospital NIH-funded |
| Lab location | 1 site (London, United Kingdom) |
| Project ID | NIH-11059609 on NIH RePORTER |
What this research studies
This research focuses on creating innovative therapies to target specific proteins that drive solid tumors in children, particularly those that are difficult to treat with traditional methods. By utilizing advanced techniques like CRISPR-Cas9 and targeted protein degradation, the team aims to identify and inhibit the unique biological mechanisms behind these tumors. The approach involves a collaborative effort from experts in various fields, ensuring a comprehensive strategy to improve treatment outcomes for young patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with solid tumors driven by specific oncogenic proteins.
Not a fit: Patients with solid tumors that do not involve the targeted oncogenic drivers or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for children suffering from solid tumors, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting oncogenic drivers in pediatric cancers, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
London, United Kingdom
- The Institute of Cancer Research: Royal Cancer Hospital — London, United Kingdom (Active)
Researchers
- Principal investigator: Chesler, Louis — The Institute of Cancer Research: Royal Cancer Hospital
- Study coordinator: Chesler, Louis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.